




RealRate

PHARMACEUTICAL 2018

Atossa Therapeutics INC
Rank 168 of 332



The relative strengths and weaknesses of Atossa Therapeutics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Atossa Therapeutics INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 87% points. The greatest weakness of Atossa Therapeutics INC is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 63% points.

The company's Economic Capital Ratio, given in the ranking table, is 267%, being 15% points above the market average of 252%.

Input Variable	Value in 1000 USD
Assets, Current	7,898
Cost of Goods Sold	0
Intangible Assets	76
Liabilities, Current	1,225
Liabilities, Non-Current	0
Other Assets	179
Other Compr. Net Income	0
Other Expenses	935
Other Liabilities	0
Other Net Income	0.15
Other Revenues	0
Property and Equipment	11
Research and Development	2,328
Selling, General and Administrative Expense	4,859

Output Variable	Value in 1000 USD
Assets	8,164
Liabilities	1,225
Expenses	8,123
Revenues	0
Stockholders Equity	6,939
Net Income	-8,123
Comprehensive Net Income	-8,123
BaseVar	8,756
ECR before LimitedLiability	149%
Economic Capital Ratio	267%